Navigate on publiceye.ch
Quick navigation
Content
Homepage
Navigation
Sitemap
Search
Main navigation
What we do
Get involved
About Public Eye
Our Publications
Reports & Factsheets
Newsletter
Social Media
Our topics
Commodities
Corruption
Fashion
Investigation Award
Pesticides
Pharma
Seeds
Soft Commodities
Trade policy
War on Ukraine
Archive
Close
Membership
Become a member
Donations and Bequests
Donate
Legacies and bequests
Get involved
Follow us
Close
About us
Portrait
Organisation
Team
The Governing Board
History
Jobs
Service
Media corner
Contact
Close
Open search forn
Reports & Factsheets
en
Change language. Current language: English
Deutsch
Français
English
Close
Donate
Open menu
Search term
Search
Close search
Search term
Search
What we do
Our Publications
Reports & Factsheets
Newsletter
Social Media
Our topics
Commodities
Corruption
Fashion
Investigation Award
Pesticides
Pharma
Seeds
Soft Commodities
Trade policy
War on Ukraine
Archive
Get involved
Membership
Become a member
Donations and Bequests
Donate
Legacies and bequests
Get involved
Follow us
About Public Eye
About us
Portrait
Organisation
Team
The Governing Board
History
Jobs
Service
Media corner
Contact
Change language. Current language: English
DE
FR
EN
Close menu
Tag
Roche
40 to 90 percent profit margins
Astronomical profit margins of pharmaceutical companies are partly to blame for the premium shock
12. September 2022
Report
Big Pharma takes it all
2021
Patent abuse, lack of transparency, profiteering
How Covid-19 exposes Big Pharma’s harmful business strategies
9. March 2021
Clinical trials
Roche and Novartis neglect their ethical responsibility in emerging countries
20. May 2019
Press Release
Roche and the Royal Bank of Canada: Worthy Public Eye Award Winners
27. January 2010
Medicines
No secret deals
No secret deals
Pricing models that benefit the pharma industry
No secret deals
A dangerous precedent for the Law on Transparency